THOMAS DAG HORN, MD
Osteopathic Medicine at Markham St, Little Rock, AR
License number
Arkansas E-1269
Category
Osteopathic Medicine
Type
Dermatology
License number
Arkansas E-1269
Category
Osteopathic Medicine
Type
Dermatopathology
Address
Address
4301 W Markham St #576, Little Rock, AR 72205
Phone
(501) 686-5110
Personal information
See more information about THOMAS DAG HORN at radaris.comName
Address
Phone
4857 Horn Ln, Springdale, AR 72764
3612 Vernon St, White Hall, AR 71602
419 W Swan St, Walnut Ridge, AR 72476
74 Carmel Dr, Little Rock, AR 72212
2 Canova Ln, Bella Vista, AR 72714
Professional information
See more information about THOMAS DAG HORN at trustoria.com
Thomas Dag Horn, Little Rock AR
Thomas Dag Horn, Little Rock AR
Specialties:
Dermatologist
Address:
4301 W Markham St, Little Rock, AR 72205
Board certifications:
American Board of Dermatology Certification in Dermatology, American Board of Dermatology Sub-certificate in Dermatopathology (Dermatology)
Dr. Thomas D Horn, Boston MA - MD (Doctor of Medicine)
Dr. Thomas D Horn, Boston MA - MD (Doctor of Medicine)
Specialties:
Dermatopathology
Address:
Dermatology Assocs MA Gen Hosp
50 Staniford St SUITE 200, Boston 02114
(617) 726-2914 (Phone)
50 Staniford St SUITE 200, Boston 02114
(617) 726-2914 (Phone)
Certifications:
Dermatology, 1987, Dermatopathology, 1988
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
Dermatology Assocs MA Gen Hosp
50 Staniford St SUITE 200, Boston 02114
Uams Medical Center
4301 West Markham St, Little Rock 72205
50 Staniford St SUITE 200, Boston 02114
Uams Medical Center
4301 West Markham St, Little Rock 72205
Education:
Medical School
Univ Of Va Sch Of Med Hlth Sys
Graduated: 1982
University Va
Graduated: 1983
University Md
Graduated: 1987
Johns Hopkins Hospital
Univ Of Va Sch Of Med Hlth Sys
Graduated: 1982
University Va
Graduated: 1983
University Md
Graduated: 1987
Johns Hopkins Hospital
Thomas D Horn, Boston MA
Thomas D Horn, Boston MA
Specialties:
Dermatology, Dermatopathology, Cardiology, Dermatopathology
Work:
Mass General Hospital
55 Fruit St, Boston, MA 02114 Cohen Dermatopathology
320 Needham St, Newton Upper Falls, MA 02464 Lahey Clinic
41 Mall Rd, Burlington, MA 01803 Dermatology Associates
50 Staniford St, Boston, MA 02114 Thomas D Cain
4120 W Markham St, Little Rock, AR 72205
55 Fruit St, Boston, MA 02114 Cohen Dermatopathology
320 Needham St, Newton Upper Falls, MA 02464 Lahey Clinic
41 Mall Rd, Burlington, MA 01803 Dermatology Associates
50 Staniford St, Boston, MA 02114 Thomas D Cain
4120 W Markham St, Little Rock, AR 72205
Education:
University of Virginia (1982) Dermatology
Immunotherapy Of Epithelial Tumors Using Intralesional Injection Of Antigens That Induce A Delayed Type Hypersensitivity Reaction
Immunotherapy Of Epithelial Tumors Using Intralesional Injection Of Antigens That Induce A Delayed Type Hypersensitivity Reaction
US Patent:
6350451, Feb 26, 2002
Filed:
Jun 25, 1999
Appl. No.:
09/344357
Inventors:
Thomas Dag Horn - Little Rock AR
Sandra Marchese Johnson - Little Rock AR
Sandra Marchese Johnson - Little Rock AR
Assignee:
The Board of Trustees of the University of Arkansas - Little Rock AR
International Classification:
A61K 3900
US Classification:
4241841, 4241931, 42419611, 4242011, 4242121, 4242741, 424 852
Abstract:
The present immunotherapy relates to a method of treating epithelial tumors and the pharmaceutical compositions and kits useful in treating such tumors. The immunotherapy comprises injecting an effective amount of a pharmaceutical composition containing at least one antigen into the tumor, wherein the antigen is selected for inducing or having the ability to induce a cutaneous delayed type hypersensitivity (DTH) response in the subject prior to the injection of the antigen into the tumors. This immunotherapy is particularly useful in treating epithelial tumors, such as warts or verrucae, that are induced by or related to papillomavirus. Antigens useful in the present immunotherapy are anergy panel antigens, such as killed mumps virus, candida extract, trichophyton extract or comparable antigenic extracts. Additionally, the method optionally includes the injection of an effective amount of at least one cytokine or colony stimulating factor into the tumor either simultaneously with or sequentially to the injection of the antigen. The subject treated by the present immunotherapy is preferably a mammal selected from a human, canine, bovine, feline, equine, ovine or rabbit subject.
Immunotherapy Of Epithelial Tumors Using Intralesional Injection Of Antigens That Induce A Delayed Type Hypersensitivity Reaction
Immunotherapy Of Epithelial Tumors Using Intralesional Injection Of Antigens That Induce A Delayed Type Hypersensitivity Reaction
US Patent:
7846447, Dec 7, 2010
Filed:
Mar 19, 2008
Appl. No.:
12/077508
Inventors:
Thomas Dag Horn - Little Rock AR, US
Sandra Marchese Johnson - Little Rock AR, US
Sandra Marchese Johnson - Little Rock AR, US
Assignee:
The Board of Trustees of the University of Arkansas - Little Rock AR
International Classification:
A61K 39/00
US Classification:
4241841, 514 2, 424 854
Abstract:
The pharmaceutical composition is useful for treating epithelial tumors in a subject and contains at least two antigens and a pharmaceutically acceptable carrier, where each of the antigens induces or is capable of inducing a cutaneous delayed type hypersensitivity (DTH) response in the subject. This composition is particularly useful in treating epithelial tumors, such as warts or verrucae, that are induced by or related to papillomavirus. Antigens useful in the present pharmaceutical composition are anergy panel antigens, such as killed mumps virus, candida extract, trichophyton extract or comparable antigenic extracts. An additional pharmaceutical composition, also useful for treating epithelial tumors, contains at least one antigen that induces or is capable of inducing a cutaneous DTH response in a subject, at least one cytokine or colony stimulating factor and a pharmaceutically acceptable carrier. Kits containing these pharmaceutical compositions are useful for this immunotherapy.
Immunotherapy Of Epithelial Tumors Using Intralesional Injection Of Antigens That Induce A Delayed Type Hypersensitivity Reaction
Immunotherapy Of Epithelial Tumors Using Intralesional Injection Of Antigens That Induce A Delayed Type Hypersensitivity Reaction
US Patent:
2005017, Aug 11, 2005
Filed:
Feb 21, 2005
Appl. No.:
11/061996
Inventors:
Thomas Horn - Little Rock AR, US
Sandra Johnson - Dublin OH, US
Sandra Johnson - Dublin OH, US
International Classification:
A61K039/12, A61K039/00
US Classification:
424204100, 424274100, 424277100
Abstract:
The pharmaceutical composition is useful for treating epithelial tumors in a subject and contains at least two antigens and a pharmaceutically acceptable carrier, where each of the antigens induces or is capable of inducing a cutaneous delayed type hypersensitivity (DTH) response in the subject. This composition is particularly useful in treating epithelial tumors, such as warts or verrucae, that are induced by or related to papillomavirus. Antigens useful in the present pharmaceutical composition are anergy panel antigens, such as killed mumps virus, extract, extract or comparable antigenic extracts. An additional pharmaceutical composition, also useful for treating epithelial tumors, contains at least one antigen that induces or is capable of inducing a cutaneous DTH response in a subject, at least one cytokine or colony stimulating factor and a pharmaceutically acceptable carrier. Kits containing these pharmaceutical compositions are useful for this immunotherapy.
Immunotherapy Of Epithelial Tumors Using Intralesional Injection Of Antigens That Induce A Delayed Type Hypersensitivity Reaction
Immunotherapy Of Epithelial Tumors Using Intralesional Injection Of Antigens That Induce A Delayed Type Hypersensitivity Reaction
US Patent:
2002014, Oct 3, 2002
Filed:
Feb 25, 2002
Appl. No.:
10/081185
Inventors:
Thomas Horn - Little Rock AR, US
Sandra Johnson - Little Rock AR, US
Sandra Johnson - Little Rock AR, US
Assignee:
University of Arkansas
International Classification:
A61K039/295, A61K039/116, A61K039/12
US Classification:
424/204100, 424/201100, 424/203100
Abstract:
The pharmaceutical composition is useful for treating epithelial tumors in a subject and contains at least two antigens and a pharmaceutically acceptable carrier, where each of the antigens induces or is capable of inducing a cutaneous delayed type hypersensitivity (DTH) response in the subject. This composition is particularly useful in treating epithelial tumors, such as warts or verrucae, that are induced by or related to papillomavirus. Antigens useful in the present pharmaceutical composition are anergy panel antigens, such as killed mumps virus, candida extract, trichophyton extract or comparable antigenic extracts. An additional pharmaceutical composition, also useful for treating epithelial tumors, contains at least one antigen that induces or is capable of inducing a cutaneous DTH response in a subject, at least one cytokine or colony stimulating factor and a pharmaceutically acceptable carrier. Kits containing these pharmaceutical compositions are useful for this immunotherapy.